Literature DB >> 20527684

Risk factors. CD8+:FOXP3+ cell ratio is a novel survival marker for colorectal cancer.

Rebecca Kirk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20527684     DOI： 10.1038/nrclinonc.2010.79

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer.

Authors:  Hiroyuki Suzuki; Nobuhito Chikazawa; Takehiko Tasaka; Junji Wada; Akio Yamasaki; Yoshiki Kitaura; Masae Sozaki; Masao Tanaka; Hideya Onishi; Takashi Morisaki; Mitsuo Katano
Journal:  Cancer Immunol Immunother       Date:  2009-11-12       Impact factor: 6.968
  1 in total
  4 in total

1.  Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.

Authors:  Vanessa Deschoolmeester; Marc Baay; Filip Lardon; Patrick Pauwels; Marc Peeters
Journal:  Cancer Microenviron       Date:  2011-05-27

Review 2.  Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis.

Authors:  Massimo Pancione; Guido Giordano; Andrea Remo; Antonio Febbraro; Lina Sabatino; Erminia Manfrin; Michele Ceccarelli; Vittorio Colantuoni
Journal:  J Immunol Res       Date:  2014-01-16       Impact factor: 4.818

3.  Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing.

Authors:  Miran Jang; Poh-Yin Yew; Kosei Hasegawa; Yuji Ikeda; Keiichi Fujiwara; Gini F Fleming; Yusuke Nakamura; Jae-Hyun Park
Journal:  Oncoimmunology       Date:  2015-04-14       Impact factor: 8.110

4.  Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.

Authors:  M Linch; G Goh; C Hiley; Y Shanmugabavan; N McGranahan; A Rowan; Y N S Wong; H King; A Furness; A Freeman; J Linares; A Akarca; J Herrero; R Rosenthal; N Harder; G Schmidt; G A Wilson; N J Birkbak; R Mitter; S Dentro; P Cathcart; M Arya; E Johnston; R Scott; M Hung; M Emberton; G Attard; Z Szallasi; S Punwani; S A Quezada; T Marafioti; M Gerlinger; H U Ahmed; C Swanton
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.